The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results